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Abstract
Purpose To investigate the impact of primary gross tumor volume (pGTV) and nodal gross tumor volume (nGTV)
in oropharyngeal squamous cell carcinoma (OPSCC) and the difference in their role between human papillomavirus
(HPV)-positive and HPV-negative patients.
Methods The patient cohort consists of 91 OPSCC patients treated with definitive radiochemotherapy or radiotherapy using
intensity-modulated radiotherapy (IMRT). All patients had a minimum follow-up of 31 months. Volume measurements
were made from computer tomography (CT) scans and HPV status was assessed by p16 immunohistochemistry. The end
points were as follows: overall survival (OS), disease-free survival (DFS) and locoregional control (LRC).
Results pGTV was a significant independent prognostic factor for overall survival (OS; p=0.020) in p16-negative patients.
nGTV of p16-negative tumors had significant prognostic value in all end points in multivariate analyses. High-stage
(III–IVc) p16-negative tumors were only associated with significantly poorer OS (p= 0.046) but not with poorer LRC or
DFS when compared with the low-stage (I–II) tumors. nGTV of p16-positive tumors was an independent prognostic factor
for DFS (p= 0.005) and LRC (p= 0.007) in multivariate analyses.
Conclusion pGTV may serve as an independent prognostic factor in p16-negative patients and nGTV may serve as an
independent prognostic factor both in p16-positive and p16-negative patients treated with radiochemotherapy or radiother-
apy using IMRT. Tumor volume may have an impact on selecting patients for de-escalation protocols in the future, both
in p16-positive and p16-negative patients.
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Tumorvolumen als prognostischerMarker bei p16-positiven und p16-negativen Patientenmit
Oropharyngealkarzinomunter Therapiemit definitiver intensitätsmodulierter Strahlentherapie
Zusammenfassung
Zielstellung Ziel war es, die Bedeutung des makroskopischen Tumorvolumens des Primärtumors („primary gross tumor
volume“, pGTV) und des makroskopischen Tumorvolumens der Lymphknoten („nodal gross tumor volume“, nGTV) bei
Plattenepithelkarzinomen des Oropharynx („oropharyngeal squamous cell carcinoma“, OPSCC) und deren Unterschiede
zwischen für humanes Papillomavirus (HPV) positiven und HPV-negativen Patienten zu untersuchten.
 Timo Carpén, MD
timo.carpen@fimnet.fi
Extended author information available on the last page of the
article
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Methoden In die Studie eingeschlossen wurden 91 OPSCC-Patienten, die mit definitiver intensitätsmodulierter Strahlen-
therapie („intensity-modulated radiotherapy“, IMRT) mit oder ohne gleichzeitige Chemotherapie behandelt wurden. Bei
allen Patienten betrug der Nachbeobachtungszeitraum mindestens 31 Monate. Die Volumenmessungen erfolgten anhand
von Computertomographie(CT)-Aufnahmen. Der HPV-Status wurde durch die p16-Immunhistochemie ermittelt. Die End-
punkte waren Gesamtüberleben („overall survival“, OS), krankheitsfreies Überleben („disease-free survival“, DFS) und
lokoregionale Kontrolle („locoregional control“, LRC).
Ergebnisse Das pGTV war ein signifikanter unabhängiger prognostischer Faktor für das OS (p=0,20) bei p16-negativen
Patienten. Das nGTV von p16-negativen Tumoren wies einen signifikanten prognostischen Wert für alle Endpunkte in
multivariaten Analysen auf. p16-negative Tumoren in hohen Stadien (III-IVc) waren im Vergleich zu den Tumoren in
niedrigeren Stadien (I-II) nur mit einem signifikant schlechteren OS (p=0,046), nicht aber mit schlechteren Werten für
LRC oder DFS assoziiert. Das nGTV von p16-negativen Tumoren erwies sich in multivariaten Analysen als unabhängiger
prognostischer Faktor für DFS (p=0,005) und LRC (p=0,007).
Schlussfolgerung Das pGTV kann als unabhängiger prognostischer Faktor bei p16-negativen Patienten und das nGTV
als unabhängiger prognostischer Faktor sowohl bei p16-positiven als auch bei p16-negativen Patienten dienen, bei denen
eine Radiochemotherapie oder Strahlentherapie unter Verwendung der IMRT erfolgt. Das Tumorvolumen kann bei der
Auswahl der Patienten für ein Deeskalationsprotokoll sowohl bei p16-positiven als auch bei p16-negativen Patienten eine
Rolle spielen.
Schlüsselwörter Humanes Papillomavirus · Überleben · Onkologie · Radiochemotherapie · Marker
Introduction
Increasing evidence exists for the role of primary gross tu-
mor volume (pGTV) and nodal gross tumor volume (nGTV)
as prognostic markers in head and neck cancer (HNSCC),
especially in oropharyngeal squamous cell carcinoma (OP-
SCC). Higher pGTV has been shown to correlate with in-
creased risk of recurrence and poorer survival [1–10]. The
suggestion for this phenomenon is that a larger tumor con-
tains a higher number of clonogenic cells, which may im-
pair treatment response to radiotherapy [11–13]. Patients
with larger tumor volumes may need to be treated with
a higher dose of radiotherapy to achieve a favorable treat-
ment response, whereas smaller tumor volumes may need
lower doses of radiotherapy and thus avoid toxic side effects
of the treatment [10, 14].
The tumor, node, metastasis (TNM) classification is
a validated standard tool for prognostic evaluation of OP-
SCC management according to disease stage. It is based on
tumor dimensions and extension with metric and anatomic
criteria [15, 16]. However, previous studies have indicated
that tumor volume as a prognostic factor may be superior
to TNM staging among patients treated with radiotherapy
[3, 6, 9, 10, 17]. The limitation of TNM classification
and staging is that the system may classify tumors with
different volumes into the same stage due to one-dimen-
sional determination [3, 6, 10, 18]. The benefit of volume
measuring is the information of exact three-dimensional
structure of the tumor and estimation of the total tumor
mass [1, 3, 6]. Furthermore, the recent 8th edition of the
TNM classification divides tumors by p16 status into HPV-
positive and HPV-negative OPSCC, and takes into account
extracapsular spread of nodal metastases [19, 20].
Previous studies have indicated that pGTV may have
prognostic impact on local control in OPSCC [1, 6, 13,
18]. In addition, it has been observed to carry prognostic
value also for overall survival and disease-free survival [1,
3, 6]. As is well-known, a clear majority of OPSCCs are
HPV positive in the Western countries, with more favorable
outcome and response to (chemo)radiotherapy compared
to HPV-negative tumors [21–25]. However, there is still
an unexplained variation in OPSCC prognosis and treat-
ment outcome irrespective of HPV status. Tumor volume
as a prognostic factor has been studied in OPSCC patients
[17] in general, and separately only in p16-positive patients
[17]; studies comparing p16-negative and p16-positive tu-
mors are still missing. In addition, clear cut-off values for
volumes predicting poorer survival remain unknown and
the previous studies were done with the 7th edition of TNM
classification. Our aim was to study the prognostic value
of primary and nodal tumor volume in p16-positive and




The inclusion criteria for the study were newly diag-
nosed biopsy-proven OPSCC patients with available tumor
p16 status treated with radiochemotherapy or radiother-
apy using IMRT. Patients with distant metastases or who
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underwent neck dissection and primary tumor resection
before radiotherapy as well as patients treated with pallia-
tive intent were excluded. CONSORT diagram of patient
selection is shown in Fig. 1. Altogether, there were 91
consecutive OPSCC patients who met the inclusion criteria
and who had been treated at the Departments of Oncology
and Otorhinolaryngology—Head and Neck Surgery at the
Helsinki University Hospital, Helsinki, Finland during a 3-
year time period between January 2012 and December
2014. An institutional study permission was granted for the
study design.
Clinical data were collected from electronic medical
records. Data included gender, age at the date of OPSCC
diagnosis, tobacco smoking status, and the date of radi-
ation treatment termination. History of tobacco smoking
was defined as “non-smoker” or ex-smoker/current smoker.
Ex-smoker was defined as a user who had more than a 1-
year history of tobacco smoking. Tumor spread and stage
were evaluated according to the 8th edition of the TNM
classification.
Oropharyngeal squamous cell 
carcinoma during 2012 - 2014 (n = 
169)
Excluded (n = 78)
 Treatment with palliative intent (n = 23)
 Surgery as primary treatment modality
 Second primary at the time of OPSCC 
diagnosis (n = 2)
Lost to follow-up (n = 0)
Radiochemotherapy/radiotherapy using IMRT as 
primary treatment with available p16 status (n = 91)




p16 negative (n = 19)
(n = 53)
Fig. 1 A CONSORT diagram of patient selection. OPSCC oropharyn-
geal squamous cell carcinoma, IMRT intensity-modulated radiotherapy
Primary and nodal tumor volume evaluation
The pGTV and nGTV were calculated three dimensionally
from CT scans by an experienced head and neck radiation
oncologist using Varian Eclipse® radiotherapy treatment
planning system versions 10.0 and 11.0 (Varian Medical
Systems Inc., Palo Alto, CA, USA). The volume results are
given in cubic centimeters (cm3). We often use combined
MRI and CT imaging for radiotherapy dose planning. MRI
was, however, not done for all patients and we therefore
we used CT for volume measurements. Different imaging
modalities may produce significantly different GTVs [26,
27]. Thus, using MRI measures in the patients for whom
it was available and CT-based volumes for the rest of the
patients could have resulted in non-comparable GTV vol-
umes. The radiotherapy planning CT was done with con-
trast enhancement in all patients using Omnipaque™ injec-
tion 350mg I/ml solution. In addition, nodal involvement
was defined according to generally accepted criteria, where
a minimal axial diameter of 10mm was the size criterion
in the digastric region for the lymph nodes and the size
criterion in the subdigastric region was 11mm [28]. In ad-
dition, lymph node necrosis and cystic lymph node metas-
tases were defined according to generally accepted criteria
[28, 29].
p16-INK4a immunohistochemistry
We detected the p16-INK4a status by immunohistochem-
istry on paraffin-embedded formalin-fixed tissue samples.
Positive p16 expression was defined when over 70% of
tumor cells were positive. Xylene was used for deparaf-
finization and rehydration was done in graded series of al-
cohol. “PreTreatment module” (Lab Vision Corp., UK) was
used to treat the tissue slides in Tris-HCl buffer (pH 8.5),
and endogenous peroxidase was blocked with 0.3% Dako
REAL Peroxidase-Blocking Solution. Monoclonal mouse
anti-human p16-INK (9517 CINtec Histology Kit, MTM
laboratories, Germany) was used as primary antibody.
Radiotherapy and chemotherapy
All tumors were treated with curative intent by radiochemo-
therapy or radiotherapy using IMRT up to 70 Gray (Gy),
in 2Gy fractions per day with or without platinum-based
chemotherapy. In addition, elective nodal areas were treated
up to 50Gy. Chemotherapy consisted of cisplatin 40mg/m2
given weekly during the radiotherapy.
Follow-up time
Follow-up time was defined as a time in months from the
date of treatment termination to the date of last follow
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up. Follow-up appointments were planned every 3 months
in the first year after completion of treatment, every 3 to
4 months in the second year, and in the next 3 years every
6 months.
Statistical analysis
Data were analyzed with a statistical software program
(IBM SPSS Statistics 24, IBM, Somers, IL, USA). The
primary endpoints were overall survival (OS), disease-free
survival (DFS), and locoregional control (LRC) separately
for p16-positive and p16-negative patients. Survival time
was defined as time in months from the completion of treat-
ment to the date of last follow-up or death. Locoregional
failure was defined as tumor residual or a biopsy-proven
recurrence locally or regionally during follow-up.
All analyses were conducted separately with pGTV and
nGTV in p16-positive and p16-negative patients. Survival
curves of dichotomized groups were calculated by the Ka-
plan–Meier method, and compared using Breslow tests.
Cox regression hazard models were used for multivariate
analyses evaluating OS, LRC, and DFS. Each of the poten-
tial prognostic factors (pGTV, nGTV, T category, N cate-
gory, and stage) were analyzed in separate Cox regression
multivariate models. The models were adjusted for age and
gender as they are general clinically relevant factors. The
results are presented as mean, median, or number of patients
when appropriate. Continuous variables and dichotomized
groups’ relationships were assessed by eta correlation co-
efficient. A two-sided p-value of less than 0.05 was consid-
ered statistically significant.
Results
Clinical patient and tumor data of 91 newly diagnosed
oropharyngeal cancer cases were evaluated. Majority of
the patients were male (72, 79.1%) and the mean age was
62 years (range 41.4–84.7 years). All patients had a mini-
mum follow-up time of 31 months.
Immunohistochemical p16 status was determined for all
cases. There were 72 (79.1%) p16-positive and 19 (20.9%)
p16-negative cases. All expect 11 (12.1%) patients un-
derwent definitive radiochemotherapy using IMRT. The
reasons for the 11 patients receiving IMRT only with-
out chemotherapy were as follows: small primary tumor
size without regional metastases for two patients, age over
80 years for three, and high serum creatinine levels or other
comorbidities for six. All the patient- and tumor-related
demographic parameters are summarized in Table 1.
Table 1 Patient- and tumor-related demographic parameters accord-





61 (41.4–84.7) 66 (54.9–81.7)
Male gender (%) 58 (80.6%) 14 (73.7%)








T category T1: 15 (20.8%) T1: 2 (10.5%)
T2: 29 (40.3%) T2: 8 (42.1%)
T3: 11 (15.3%) T3: 0 (0.0%)
T4: 17 (23.6%) T4a: 6 (31.6%)
T4b: 3 (15.8%)
N category N0: 6 (8.3%) N0: 10 (52.6%)
N1: 55 (76.4%) N1: 2 (10.5%)
N2: 10 (13.9%) N2a: 0 (0.0%)
N2b: 2 (10.5%)
N2c: 1 (5.3%)
N3: 1 (1.4%) N3a: 0 (0.0%)
N3b: 4 (21.1%)
Clinical stage I: 39 (54.2%) I: 2 (10.5%)
II: 15 (20.8%) II: 7 (36.8%)
III: 18 (25.0%) III: 0 (0.0%)
IV: 0 (0.0%) Iva: 4 (21.1%)
IVb: 6 (31.6%)
IVc: 0 (0.0%)
Mean pGTV (SD) 23cm3 (29.03) 38cm3 (45.87)
Median pGTV
(range)
14cm3 (1–190) 19cm3 (2–147)
Mean nGTV (SD) 26cm3 (34.12) 13cm3 (34.22)
Median nGTV
(range)
15cm3 (0–200) 0cm3 (0–142)
pGTV primary tumor volume, nGTV nodal tumor volume, SD standard
deviation
p16 status and survival
OS (p< 0.001), LRC (p< 0.001), and DFS (p< 0.001) rates
were significantly more favorable among p16-positive pa-
tients compared with p16-negative patients during the
whole follow-up. For p16-positive patients, the estimated
2-year OS was 93.1% (67/72), DFS 87.5% (63/72), and
LRC 93.1% (67/72), whereas for p16-negative patients, OS
was 63.2% (12/19), DFS 57.9% (11/19), and LRC 68.4%
(13/19). Distant metastases occurred only in two p16-
positive patients and in two p16-negative patients during
the whole follow-up and therefore the effect of this phe-
nomenon on survival could not be evaluated statistically.
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Table 2 Impact of primary gross tumor volume (pGTV), nodal gross tumor volume (nGTV), T category, N category, and stage on overall survival










OS (p16+) OS (p16–)
pGTV 0.336 1.01 0.99–1.02 pGTV 0.020* 1.02 1.00–1.04
T category 0.857 0.90 0.27–2.99 T category 0.096 4.27 0.77–23.57
nGTV 0.965 1.00 0.98–1.02 nGTV 0.027* 1.02 1.00–1.04
N category 0.130 2.85 0.74–11.07 N category 0.150 3.28 0.65–16.52
Stage 0.060 3.26 0.95–11.17 Stage 0.046* 9.86 1.05–93.03
DFS (p16+) DFS (p16–)
pGTV 0.364 1.01 0.99–1.02 pGTV 0.106 1.01 0.99–1.03
T category 0.825 0.89 0.30–2.59 T category 0.368 1.85 0.49–7.03
nGTV 0.005* 1.02 1.01–1.03 nGTV 0.022* 1.02 1.00–1.04
N category 0.361 1.82 0.50–6.64 N category 0.366 1.88 0.48–7.44
Stage 0.059 2.80 0.96–8.18 Stage 0.185 2.62 0.63–10.93
LRC (p16+) LRC (p16–)
pGTV 0.839 1.00 0.96–1.05 pGTV 0.162 1.01 0.99–1.03
T category 0.740 1.32 0.26–6.60 T category 0.350 2.12 0.44–10.17
nGTV 0.007* 1.03 1.01–1.05 nGTV 0.017* 1.02 1.00–1.04
N category 0.805 1.31 0.15–11.42 N category 0.117 3.63 0.73–18.19
Stage 0.290 2.34 0.47–12.14 Stage 0.139 3.82 0.65–22.58
Each factor is analyzed in a separate multivariate Cox regression model where age and gender are adjusted. pGTV and nGTV are continuous
variables
*p< 0.05
pGTV primary tumor volume, nGTV nodal tumor volume, OS overall survival, DFS disease-free survival, LRC locoregional control, CI confidence
interval, HR hazard ratio
Tumor volume and prognosis in p16-negative
patients
The mean pGTV for p16-negative tumors was 38cm3
(standard deviation, SD, 45.87) and median 19cm3 (range
1–147). pGTV as a continuous variable in a multivariate
model in p16-negative patients showed an independent sta-
tistically significant impact on OS (p= 0.020; hazard ratio,
HR, 1.02; 95% confidence interval, CI95%, 1.00–1.04) but
not in LRC or DFS when age and gender were adjusted
(Table 2). Furthermore, for different analyses, T cate-
gories of p16-negative tumors were distributed to low
(T1–T2) and high (T3–T4b) T category groups. Small and
large T categories groups were analyzed and compared in
a similar multivariate model as above, without showing
any significant prognostic value in any of the endpoints
(Table 2). Due to high reciprocal correlation (eta corre-
lation coefficient 0.978), it was not possible to present
different T categories and pGTV in the same multivariate
Cox regression model.
For the survival analyses and in order to assess clear
survival cut-off values, pGTV of p16-negative tumors was
also dichotomized by its mean value to small (38cm3)
and large volumes (>38cm3) and by its median value to
small (19cm3) and large volumes (>19cm3). The group of
large pGTV (>38cm3) had statistically significantly poorer
OS (p= 0.005) and DFS (p= 0.028), and closely but not
significantly poorer LRC (p= 0.062) compared with the
small pGTV group. Furthermore, when dichotomized and
compared by its median value, large pGTV (>19cm3) was
associated with significantly poorer DFS (p= 0.049) and
LRC (p= 0.029), and closely but not significantly poorer
OS (p= 0.064) when compared with the small pGTV
(19cm3) group. As with the p16-positive patients, we
also dichotomized T categories of p16-negative patients to
small (T1–T2) and large (T3–T4b) T category groups. We
found no significant differences in OS (p= 0.263), DFS
(p= 0.458), or LRC (p= 0.371) between these two groups
by Breslow test in Kaplan–Meier curves (Fig. 2) or in
multivariate models (Table 2).
The mean nGTV for p16-negative tumors was 13cm3
(SD 34.22) and median 0cm3 (range 0–142). As a continu-
ous variable, nGTV in p16-negative patients showed an in-
dependent statistically significant impact on OS (p= 0.027,
HR 1.02, CI95% 1.01–1.04), LRC (p= 0.017, HR 1.02,
CI95% 1.00–1.04), and DFS (p= 0.022, HR 1.02, CI95%
1.00–1.04) in a multivariate model (Table 2). nGTV di-
chotomized by its mean value to small and large volume
groups did not show any differences in any of the end-
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Fig. 2 Impact of mean primary gross tumor volume (pGTV; a), T category (b), N category (c), and stage (d) on overall survival (OS) in
p16-negative patients
points. nGTV could not be dichotomized by its median
value (0cm3).
For further analyses, N categories were dichotomized
to low (N0–N2a) and high (N2b–N3b) N category groups.
We found no significant differences in OS (p= 0.548), DFS
(p= 0.685), or LRC (p= 0.284) between these two groups
by using Breslow test or in multivariate models. Clinical
stage of p16-negative tumors where dichotomized to low
(I–II) and high (III–IVc) stages. High-stage group (III–IVc)
was associated with statistically significantly poorer OS
(p= 0.046, HR 9.86, CI95% 1.05–93.03) but not with poorer
LRC or DFS in multivariate models (Table 2). In addition,
high-stage (III–IVc) group had no significant difference in
OS (p= 0.169), DFS (p= 0.362), or LRC (p= 0.234) when
compared with the low-stage (I–II) group. All the results
of multivariate analyses are shown in Table 2. Survival dif-
ferences between different groups of pGTV, T category,
N category, and stage on OS in p16-negative patients are
shown as Kaplan–Meier curves in Fig. 2 and on LRC in
Fig. 3.
Tumor volume and prognosis in p16-positive
patients
The mean pGTV for p16-positive tumors was 23cm3 (SD
29.03) and median 14cm3 (range 1–190). As a continuous
variable pGTV showed no independent statistically signifi-
cant impact on any of the endpoints (OS, LRC, or DFS) in
p16-positive patients in a Cox regression multivariate model
when age and gender were adjusted (Table 2). Furthermore,
for different analyses, T categories of p16-positive tumors
were distributed to low (T1–T2) and high (T3–T4) T cat-
egory groups. Dichotomized T categories were analyzed
in a similar multivariate model as above and a significant
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Fig. 3 Impact of median primary gross tumor volume (pGTV; a), T category (b), N category (c), and stage (d) on locoregional control (LRC) in
p16-negative patients
prognostic value was not found in any of the endpoints (Ta-
ble 2). Due to high reciprocal correlation (eta correlation
coefficient 1.000), it was not possible to present different
T categories and pGTV in the same multivariate Cox re-
gression model.
For the survival analyses and in order to assess clear sur-
vival cut-off values, pGTV was dichotomized into two dif-
ferent volume groups by its mean value to small (23cm3)
and large volumes (>23cm3) and by its median value to
small (14cm3) and large volumes (>14cm3). We found no
significant differences in OS (p= 0.676), DFS (p= 0.662),
or LRC (p= 0.601) between small and large pGTV when
dichotomized by its mean value or for OS (p= 0.507), DFS
(p= 0.752), or LRC (p= 0.887) when dichotomized by its
median value in p16-positive patients. Furthermore, T cate-
gories were distributed to small (T1–T2) and large (T3–T4)
tumors and compared in a multivariate model without show-
ing any statistically significant impact on any of the end-
points (Table 2). Small and large T categories were also
analyzed with Breslow test as Kaplan–Meier curves, but
no significant prognostic differences were found for OS
(p= 0.895), DFS (p= 0.901), or LRC (p= 0.603).
The mean nGTV for p16-positive tumors was 26cm3
(SD 34.12) and median 15cm3 (range 0–200). As a contin-
uous variable, nGTV showed an independent statistically
significant impact on DFS (p= 0.005, HR 1.02, CI95%
1.01–1.03) in p16-positive patients in a Cox regression
multivariate model when age and gender were adjusted
(Table 2). Furthermore, large nGTV was associated with
statistically significant poorer DFS (p= 0.046) when di-
chotomized by its mean value to small (26cm3) and large
(>26cm3) volumes. Statistically significant differences were
not found in OS (p= 0.508) or LRC (p= 0.159) between
small and large nGTV when dichotomized by its mean
value. nGTV was also dichotomized and analyzed by its
median value, but significant prognostic differences in OS
(p= 0.625), DFS (p= 0.627), or LRC (p= 0.673) were not
found between small and large volumes. For comparison,
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Fig. 4 Impact of mean nodal gross tumor volume (nGTV) (a), T category (b), N category (c) and stage (d) on disease-free survival (DFS) in
p16-positive patients
we also dichotomized N categories to low (N0–N1) and
high (N2–N3) N categories and clinical stages to low (I–II)
and high (III–IV) stages. Different N categories or clinical
stages showed no prognostic differences in any of the end-
points in multivariate models when age and gender were
adjusted (Table 2). In addition, comparison of low and high
N categories showed no significant prognostic differences
in OS (p= 0.124), DFS (p= 0.328), or LRC (p= 0.806),
whereas the high clinical stage (III–IV) group had signif-
icantly poorer DFS (p= 0.041) but not OS (p= 0.056) or
LRC (p= 0.123) when compared with the low-stage (I–II)
group. Multivariate analyses are shown in Table 2. Sur-
vival differences in DFS between different groups of nGTV,
T categories, N categories, and stages in p16-positive pa-
tients are shown as Kaplan–Meier curves in Fig. 4. Finally,
an example of a treatment planning CT scan of a p16-pos-
itive tumor is illustrated in Fig. 5.
Discussion
This single-institution study on 91 OPSCC patients treated
with definitive radiochemotherapy or radiotherapy using
IMRT provides new evidence that pGTV and nGTV may
have specific roles as independent prognostic factors for the
subgroups of p16-negative and p16-positive cancers.
pGTV was found to be an independent prognostic fac-
tor in p16-negative patients for OS in multivariate analysis
where age and gender were adjusted. Large p16-negative
tumors with the mean pGTV (38cm3) as the cut-off value
were associated with significantly poorer OS and DFS, and
the trend was similar with LRC but not significant when
compared with smaller tumors. p16-negative tumors larger
than a median pGTV (>19cm3) were associated with sig-
nificantly poorer DFS and LRC, and the trend was simi-
lar for OS but not statistically significant. For comparison,
T categories, N category, and stage of p16-negative patients
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Fig. 5 P16-positive tumor (T2N2) of the base of tongue: primary
gross tumor volume (pGTV) yellow contour, nodal gross tumor vol-
ume (nGTV; left) brown contour; clinical target volume (CTV) light
blue contour; planning target volume (PTV) red contour; right sub-
mandibular gland blue contour; left submandibular gland dark blue
contour; spinal canal purple contour. Metastasis at the right side of
neck is not visualized at this level
were dichotomized into low and high groups but none had
differences in any of the endpoints. In multivariate analy-
ses of T category, N category, and stage, only stage had
prognostic impact on OS but the confidence interval was
relatively high. pGTV, T category, N category, or clinical
stage showed no significant impact on any of the endpoints
in p16-positive patients in multivariate analyses. Our find-
ings of the prognostic value of pGTV in OPSCC are in line
with previous studies [1, 3, 6, 17, 18] but we are the first
to report these findings separately in p16-positive and p16-
negative tumors and according to the newest TNM classifi-
cation [19].
nGTV of p16-negative tumors had significant prognostic
value in all endpoints in multivariate analyses but significant
differences were not found between large and small nGTV
groups when dichotomized by its mean or median value.
As a conclusion, nGTV may serve as a prognostic factor
for p16-negative patients but clear cut-off values remain un-
known. nGTV of p16-positive tumors was an independent
prognostic factor for DFS and LRC in multivariate analy-
ses and DFS was significantly poorer among large tumors
when dichotomized by mean nGTV (26cm3) to large and
small tumors. Differences in survival were not found be-
tween large and small tumors when the cut-off value was
assessed by nGTV median value (15cm3). Davis et al. 2016
had similar results of nGTV for DFS in p16-positive tumors
in multivariate analysis but they did not analyze impact of
nGTV on LRC. To our knowledge, this is the first report to
study the prognostic value of pGTV and nGTV both in mul-
tivariate analyses and with different volume cut-off values
in p16-positive tumors.
As shown in various studies [21, 25, 30], p16-positive
primary tumors are in general smaller compared with p16-
negative tumors by T category but have a tendency to
spread more often to regional lymph nodes. Despite re-
gional spreading, their response to (chemo)radiotherapy,
and thus also locoregional control, are more favorable [21,
23, 25]. Our findings are in line with previous studies show-
ing p16-negative tumors to be larger by T category, whereas
p16-positive tumors have a tendency to spread regionally
more often. In addition, the prognosis of p16-positive pa-
tients was significantly more favorable compared with p16-
negative tumors. pGTV of p16-negative tumors was clearly
larger and nGTV smaller when compared with p16-positive
tumors, which correlates with their T and N categories de-
fined with the new 8th TNM classification. However, a few
cases had different T categories or N categories despite
similar pGTV and nGTV values (data not shown). The
definition of T category and N category is based on dia-
metric and anatomic criteria [15, 16], whereas volume is
measured three-dimensionally, which seems to give a more
accurate dimension for the tumor and thus explain our find-
ings. Larger tumor mass (volume) may contain a larger
number of malignant tumor cells [11–13], which in certain
cut-off values may impair treatment response to concurrent
radiochemotherapy or radiotherapy using IMRT in OPSCC.
In addition, the differences in treatment response may be
explained by the differences in biological and genetic back-
ground of p16-positive and p16-negative tumors according
to the viral status [24, 31]. We found a significant impact of
pGTV on all endpoints in p16-negative patients depending
on mean or median cut-off values as shown above.
There are clear etiological, biological, clinical, and treat-
ment planning differences between p16-positive and p16-
negative tumors. Furthermore, the majority of newly diag-
nosed OPSCCs are currently p16-positive in Western coun-
tries [23]. Therefore, the recently launched UICC (8th edi-
tion) TNM classification includes specific criteria for p16-
positive patients [20]. The new classification also includes
extracapsular spread as a parameter for nodal extension es-
timation and thus further aids in treatment planning and
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prognostication [19, 32]. In our study, TNM classification
of the tumors was made with the newest 8th edition, which
was a clear strength of the study design compared with
previous OPSCC studies. Another study strength was a ho-
mogenous study group with a long follow-up time without
dropouts. The clear study limitations were lack of HPV de-
tection with PCR or in situ hybridization, and a relatively
small number of p16-negative patients. In addition, there
was a rather small number of events in survival analyses,
which is the consequence of successful treatment planning
and favorable response to (chemo)radiotherapy.
In previous studies of HNSCC [6, 9, 10, 13, 33], pGTV
has shown higher prognostic value compared to TNM clas-
sification as well as in the present study in p16-negative
patients. Additionally, our results on nGTV showed higher
prognostic value in multivariate analyses of p16-negative
patients and p16-positive patients. Whether this result is
partly due to the fact that all the patients in the present
series were treated with definitive radiochemotherapy or
radiotherapy using IMRT and not with a combination of
surgery and postoperative radiotherapy remains to be elu-
cidated.
In the present study, mean pGTV as a cut-off value
was closer to the point which clearly distributes tumors
to groups with either favorable or non-favorable prognosis,
as compared to the median volume. In previous studies,
pGTV cut-off values have been assessed with a large range
from 6cm3 to 70cm3 by median or mean volume without
a clear consensus [2–4, 6, 9, 18]. In the present study, larger
p16-negative tumors than mean pGTV (>38cm3) were as-
sociated with poorer OS and DFS, whereas p16-negative
tumors larger than median pGTV (>19cm3) were associ-
ated with poorer LRC. To our knowledge, this is the first
study to assess and compare cut-off value with mean and
median values in the same study cohort.
Conclusion
pGTV may serve as an independent prognostic factor in
p16-negative patients in order to predict poor treatment re-
sponse to radiochemotherapy or radiotherapy using IMRT.
nGTV may serve as an independent prognostic factor both
in p16-positive and p16-negative OPSCC treated with ra-
diochemotherapy or radiotherapy using IMRT. There are
many ongoing trials where the aim is to establish specific
patient selection criteria for de-escalation protocols. Our
findings on tumor-related factors might have an impact in
this field in the future. For this reason, future studies are
warranted with larger patient cohorts to confirm these re-
sults and in order to assess clear cut-off values for favorable
and non-favorable treatment response.
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